Sigilon Therapeutics
  • About Us
    • Our Company
      • Leadership
      • Board of Directors
      • Founders
      • Scientific Advisory Board
    • Contact Us
  • Science
    • SLTx PLatform
    • Publications
  • Pipeline
  • Patients & Caregivers
    • Overview
    • Rare Blood Disorders
    • Lysosomal Storage Diseases
    • Diabetes
  • Investors/Media
    • Investor/Media Home
    • News & Events
      • Press Releases
      • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
    • Analyst Coverage
    • Financials & Filings
      • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Leadership
      • Board of Directors
      • Committee Composition
    • Investor Relations
      • Investor FAQ
      • Email Alerts
  • Inside Sigilon
    • Our Culture
    • Job Opportunities

Publications

Medical Congresses

  • December 2020
    SIG-001
    First-in-Human Phase 1/2 Clinical Trial of SIG-001, an Innovative Shielded Cell Therapy Platform, for Hemophilia A, ASH 2020, Abstract
  • July 2020
    SIG-001
    SIG-001 for Hemophilia A: Preclinical Safety and Efficacy Studies Conducted in Mice and Non-Human Primates, ISTH 2020, Abstract
  • May 2020
    SLTx Platform
    Optimization of Shielded Encapsulated Cell Therapy for Hemophilia and Beyond, ASGCT 2020, Abstract
  • February 2020
    SIG-009
    Correcting FVII Deficiency Using Coagulation Factors Produced in Vivo by Encapsulated Engineered Allogeneic Cells, EAHAD 2020, Abstract
  • February 2020
    SIG-005
    Preclinical Development of SIG-005 for Treatment of MPS1, WORLD Symposium 2020, Abstract
  • February 2020
    SIG-007
    Preclinical Development of SIG-007 for Treatment of Fabry Disease, WORLD Symposium 2020, Abstract
  • December 2019
    SIG-001
    Correcting Rare Blood Disorders Using Coagulation Factors Produced in vivo by Shielded Living Therapeutics™ Products, ASH 2019, Abstract

Peer Reviewed Publications

  • March 30, 2020
    A Retrievable Implant for the Long-Term Encapsulation and Survival of Therapeutic Xenogeneic Cells, Nature Biomedical Engineering
  • Winter 2019-2020
    Hemophilia Federation of America's 2019-20 Special Dateline Federation Magazine: Emerging Therapies, Hemophilia Federation of America
  • August 13, 2018
    Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells transplanted into the omental bursa of macaques, Nature Biomedical Engineering
  • July 30, 2018
    Reduction of measurement noise in a continuous glucose monitor by coating the sensor with a zwitterionic polymer, Nature Biomedical Engineering
  • April 12, 2018
    Evolving Industry Partnerships and Investments in Cell and Gene Therapies, Cell Stem Cell
  • April 2, 2018
    Future Therapies Using Implanted Engineered Cells as Protein Factories, PharmTech
  • December 11, 2018
    Coated glucose sensors dodge recalibration, Nature Biomedical Engineering
  • March 20, 2017
    Colony stimulating factor-1 receptor is a central component ofthe foreign body response tobiomaterial implants in rodents and non-human primates, Nature Materials
  • January 25, 2016
    Long-term glycemic control using polymer-encapsulated human stem cell–derived beta cells in immune-competent mice, Nature Medicine
  • January 25, 2016
    Combinatorial hydrogel library enables identification of materials that mitigate the foreign body response in primates, Nature Biotechnology
  • May 18, 2015
    Size- and shape-dependent foreign body immune response to materials implanted in rodents and non-human primates, Nature Materials
©2021 Sigilon Therapeutics, Inc.
sigilon logo
The marks SIGILON THERAPEUTICS, SIGILON, SHIELDED LIVING THERAPEUTICS, SLTX, AFIBROMER, AFIBROTEK, and our logos are trademarks of Sigilon Therapeutics, Inc. in the U.S. and other countries. All other marks are the property of their respective owners.     Privacy Policy